Table 2:
Quarterly drug use over the first year of life.
| Drug | Month 3 (n = 712*) | Month 6 (n = 708*) | Month 9 (n = 688*) | Month 12 (n = 696*) | P-value** |
|---|---|---|---|---|---|
| No respiratory drug | 533 (74.9%) | 481 (67.9%) | 466 (67.7%) | 462 (66.4%) | 0.0005 |
| At least one | 179 (25.1%) | 227 (32.1%) | 222 (32.3%) | 234 (33.6%) | 0.0005 |
| Inhaled Bronchodilator | 93 (13.1%) | 184 (26.0%) | 198 (28.8%) | 218 (31.3%) | <.0001 |
| albuterol | 92 (12.9%) | 184 (26.0%) | 197 (28.6%) | 216 (31.0%) | <.0001 |
| formoterol | 0 | 1 (0.1%) | 0 | 0 | -- |
| ipratropium | 3 (0.4%) | 1 (0.1%) | 4 (0.6%) | 6 (0.9%) | 0.1294 |
| racemic epinephrine | 7 (1.0%) | 3 (0.4%) | 2 (0.3%) | 3 (0.4%) | 0.4182 |
| Diuretic | 78 (11.0%) | 41 (5.8%) | 11 (1.6%) | 11 (1.6%) | <.0001 |
| amiloride | 1 (0.1%) | 0 | 0 | 0 | -- |
| bumetanide | 1 (0.1%) | 1 (0.1%) | 0 | 2 (0.3%) | -- |
| chlorothiazide | 36 (5.1%) | 22 (3.1%) | 4 (0.6%) | 3 (0.4%) | <.0001 |
| furosemide | 30 (4.2%) | 13 (1.8%) | 6 (0.9%) | 5 (0.7%) | 0.0001 |
| hydrochlorothiazide | 23 (3.2%) | 10 (1.4%) | 4 (0.6%) | 3 (0.4%) | 0.0002 |
| spironolactone | 42 (5.9%) | 22 (3.1%) | 4 (0.6%) | 3 (0.4%) | <.0001 |
| Methylxanthine | 18 (2.5%) | 11 (1.6%) | 0 | 0 | -- |
| aminophylline | 1 (0.1%) | 0 | 0 | 0 | -- |
| caffeine | 17 (2.4%) | 11 (1.6%) | 0 | 0 | -- |
| theophylline | 1 (0.1%) | 0 | 0 | 0 | -- |
| Systemic Corticosteroid | 29 (4.1%) | 30 (4.2%) | 40 (5.8%) | 39 (5.6%) | 0.2294 |
| dexamethasone | 12 (1.7%) | 5 (0.7%) | 10 (1.5%) | 7 (1.0%) | 0.2535 |
| hydrocortisone | 10 (1.4%) | 4 (0.6%) | 2 (0.3%) | 2 (0.3%) | 0.0842 |
| methylprednisolone | 2 (0.3%) | 2 (0.3%) | 0 | 2 (0.3%) | -- |
| prednisone/prednisolone | 14 (2.0%) | 23 (3.2%) | 29 (4.2%) | 29 (4.2%) | 0.0185 |
| Inhaled Steroid | 61 (8.6%) | 70 (9.9%) | 86 (12.5%) | 99 (14.2%) | 0.0008 |
| beclomethasone | 2 (0.3%) | 5 (0.7%) | 7 (1.0%) | 10 (1.4%) | 0.0416 |
| budesonide | 51 (7.2%) | 53 (7.5%) | 57 (8.3%) | 61 (8.8%) | 0.6050 |
| fluticasone | 8 (1.1%) | 15 (2.1%) | 22 (3.2%) | 30 (4.3%) | 0.0016 |
| Leukotriene receptor antagonist | 0 | 0 | 2 (0.3%) | 3 (0.4%) | -- |
| montelukast | 0 | 0 | 2 (0.3%) | 3 (0.4%) | -- |
| Pulmonary Vasodilator | 2 (0.3%) | 7 (1.0%) | 6 (0.9%) | 6 (0.9%) | 0.1611 |
| sildenafil | 2 (0.3%) | 7 (1.0%) | 6 (0.9%) | 6 (0.9%) | 0.1611 |
*
Number of babies completing the specified follow-up visit.
**
Reported p-value for overall ‘time’ effect (df=3) for logistic generalized estimating equations model for drug use (yes/no), with working exchangeable correlation structure.